Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.
Calyx (Perceptive Informatics LLC) has entered into a strategic partnership with Ceretype Neuromedicine Inc., whose novel functional magnetic resonance imaging (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies
Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma.
Two neutralizing monoclonal antibodies isolated from volunteers vaccinated against the yellow fever virus controlled the viremia and prevented severe disease and death in hamsters and primates.
Protein tyrosine phosphatase 4A1 (PTP4A1) is known to promote tumor growth and migration of tumoral cells, but its role in the kidney has not been deeply explored. Researchers from Korea have aimed to investigate the role of PTP4A1 during kidney fibrosis and suggest it as a potential therapeutic target.
Nicorandil is a potent K(ATP) channel activator and a sulfonylurea receptor 2 (SUR2) selective agonist launched for the treatment of angina pectoris. Nicorandil binds to ATP-sensitive KATP channels in the mitochondrial inner membrane to preserve mitochondrial function during ischemia.
Researchers from Yeungnam University and collaborators presented the discovery and preclinical evaluation of novel 7-azaoxindole derivatives for their antitumor activity.
Helicobacter pylori infection and germline genetic variants interacted with each other to affect the risk of gastric cancer in a study comparing more than 11,000 patients with stomach cancer and 44,000 people without cancer. Researchers from the RIKEN Center for Integrative Medical Sciences (IMS) published those findings in the March 30, 2023, issue of the New England Journal of Medicine.
Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.
Alternative splicing aids in maintaining the complexity of the transcriptome in higher organisms, and small nuclear RNAs (snRNAs), which are major components of the spliceosome, are processed by the integrator complex. Dysfunctions of integrator complex lead to immature snRNA production and may result in secondary defects in mRNA splicing.
RSS
